

September 27, 2023

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

**Announcement of Provision of Antibody Research Support Service  
Through Single Cell Cloning Technology**

Perseus Proteomics Inc. is pleased to announce that the Company has started to provide antibody research support service utilizing single cell cloning technology.

The Company has been working on the antibody drug discovery through hybridoma technology and phage display technology, utilizing the unique phage library and the screening method. Now the Company has adopted single cell cloning technology as a new antibody obtaining method. The Company will not only utilize this technology in drug discovery business but also develop it as research support service for research and development by academia and companies.

This service enables us to obtain antibodies through isolating, screening, and selecting the cell that produces the target antibodies one by one without conventionally required processes including fusing cells and establishing libraries. The platform of the Company has been integrated with a high throughput device so that antibodies can be obtained speedily and efficiently. Also, this service is available for a wide variety of applications including analysis of single cell genes, retrieval of rare cells, and cell cloning after inserting genes.

The impact on the FY2023 business results of the Company is minor. The Company will aim to provide various services to support research activities of academia and companies.

END